Combination immunotherapy for cancer by Fearon,  D.
INSIGHTS
1114 INSIGHTS | The Journal of Experimental Medicine
TCR signaling, necessary for normal T cell development and T cell function, proceeds through the induction 
of protein phosphorylation of downstream molecules, including the membrane-anchored adaptor LAT. 
LAT, a substrate of the ZAP70 tyrosine kinase, is phosphorylated on multiple tyrosines that serve as docking 
sites for the recruitment of several effector molecules, including PLCγ1, Gads/SLP-76, and Grb2/SOS, that 
are responsible for induced increase in Ca2+ and activation of the Ras/MAPK pathway.
Human immune deficiencies often reveal unexpected functions or highlight differences between human and 
mouse immune systems. In this issue, Keller et al. describe a family with three children that are homozygous for 
LAT mutations leading to premature LAT truncation, eliminating all of its known tyrosine phosphorylation sites. 
The clinical phenotypes of these patients 
were heterogeneous, characterized by aspects 
of immune deficiency and autoimmunity. Most noteworthy, 
some T cells developed in these patients. Interestingly, stimulation 
of the TCR on the T cells of the one patient that could be studied 
resulted in a substantial calcium increase and evidence of NF-κB 
activation but no Erk activation.
The development of some T cells in these patients is sur-
prising, as are the signaling studies. Germline deletion of LAT 
in mice results in profound early thymocyte developmental 
arrest, resulting in complete absence of peripheral T cells. It is 
possible that some LAT-related molecule might compensate 
for the loss of LAT function in the human, but efforts to iden-
tify such molecules were not productive. Alternatively, the 
truncated LAT protein might not represent a complete loss-of-
function mutant. However, the authors examined the function 
of the truncated mutant in a LAT-deficient Jurkat T cell where 
they confirmed that the mutant LAT molecule did not support 
PLCγ1 phosphorylation, Ca2+ increase, Erk phosphorylation, 
or CD69 induction. Thus, the authors’ findings with the mutant 
LAT provided the expected phenotype based on previous studies 
with LAT mutants in Jurkat and in mice.
So what accounts for the preserved signaling and somewhat 
preserved T cell development in the patient cells? There is no clear explanation. The mouse and Jurkat systems may differ from 
signaling systems in human T cells. Most puzzling, however, is the observation that increases in Ca2+ and Erk, which are usually 
coupled and downstream of PLCγ1 activity, are discordant here. These studies would suggest a pathway leading to calcium 
increase that is dissociated from the activation of PLCγ1 operates in human but not in mouse or Jurkat T cells. These studies 
present an interesting and puzzling set of observations that await explanation.
Keller, B., et al. 2016. J. Exp. Med. http://dx.doi.org/10.1084/jem.20151110
Human LAT mutation results in immune deficiency  
and autoimmunity but also raises questions  
about signaling pathways
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In this issue, Chapuis et al. describe the response of a single patient with metastatic melanoma to combination 
immunotherapy with anti-CTLA4 and adoptive T cell therapy (1). Although JEM usually discourages the sub-
mission of single case studies, the editors, like the authors, realized that this patient was unusual. He had previ-
ously been treated with anti-CTLA4 and adoptive T cell therapy administered as monotherapies, with only 
possible slowing of tumor growth with the former, and no response to the latter. The subsequent complete and 
durable clinical response to simultaneous treatment with these two modalities, therefore, allowed an argument 
to be made that their combination was responsible for the improved outcome.
The efficacy of blocking antibodies to CTLA4, PD1, PD-L1, and adoptive T cell therapy, including 
CAR T cells, has been established, but only a minority of patients with certain cancers respond. The challenge 
now is to increase both the proportion of patients and the types of cancers that respond to immunological 
interventions. The finding by Chapuis et al., when taken together with an earlier demonstration of the clinical benefit of com-
bining anti-CTLA4 and anti-PD1 in patients with melanoma (2), argues that combining interventions that target different 
components of an anticancer immune response may be a feasible strategy. The question is, how will the most therapeutically 
effective combinations be determined?
Chapuis et al. combined adoptive T cell therapy with anti-CTLA4 because “an ex vivo source of melanoma-reactive CTL 
might not only provide sufficient substrate for anti-CTLA4 to enhance tumor lysis, but also trigger the development of de novo 
responses to nontargeted antigens.” Postow et al. (2) combined anti-CTLA4 and anti-PD1 because “in preclinical models, 
combined blockade of PD-1 and CTLA-4 achieved more pronounced antitumor activity than blockade of either pathway 
alone.” These clinical experiments were based on preclinical experimental work, as is appropriate. How might this rationally 
scientific pathway be enhanced?
The Chapuis et al. study also addresses this issue. Instead of being funded by the pharmaceutical industry, financial support 
was derived from the government and SU2C, a charitable program of the Entertainment Industry Foundation. This may become 
the model for cancer immunotherapy. There has been remarkable philanthropic support for this field, as exemplified not only 
by SU2C, but also by the recent gifts from Michael Bloomberg, Sidney Kimmel, and Sean Parker to establish cancer immunology 
centers at several academic institutions. This development will allow clinical investigators to focus only on science when developing 
strategies for combination immunotherapies.
1. Chapuis, A.G., et al. 2016. J. Exp. Med. http://dx.doi.org/10.1084/jem.20152021
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